UNSPSC 51181600: Thyroid and antithyroid drugs

This classification denotes preparations that treat diseases and disorders of a highly vascularized endocrine gland consisting of two lobes joined by a thin band of tissue with one lobe on each side of the trachea. it secretes thyroid hormones from the follicular cells and calcitonin from the parafollicular cells thereby regulating metabolism and calcium level in blood, respectively.

UNSPSC 51181600 Thyroid and antithyroid drugs is a Class code under which state and local governments procure generic pharmaceuticals and over-the-counter products distributed through cooperative purchasing frameworks to public facilities. The scope encompasses manufacturers supplying finished pharmaceutical products with specified National Drug Codes, strengths, dosage forms, and packaging configurations, with vendors required to maintain current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance. State and local issuing bodies include state departments of administration, multistate cooperative purchasing alliances, and participating state and local government facilities. Vendors must establish relationships with authorized pharmaceutical wholesalers, maintain comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and offer flexible pricing structures such as flat price, net price formats, or WAC-minus pricing. All products must be available in the marketplace and possess FDA compliance with minimum one-year expiration dates and six-month shelf life.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving Minnesota and Oregon state and local government facilities. The RFP (Solicitation Number S1070000015802) closed on March 26, 2026, with evaluation criteria weighted heavily toward price competitiveness (75 percent), followed by fixed pricing terms (10 percent), and administrative compliance measures including EDI capability, administrative fee agreement, and data-format compliance (5 percent each). Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co., LLC) with chargeback systems in place. Contract awards are effective July 1, 2026, with terms of two years for new responders and optional extensions at MMCAP's discretion, while incumbent vendors' amendments align with existing agreements through June 30, 2028. Specific award values are not disclosed; vendors must submit pricing in designated Excel-to-CSV format through the ePro procurement system with supporting documentation emailed to MMCAP_Infuse.RFP@state.mn.us.